This article is more than 5 years old. Information may no longer be current.

LumiThera secures $5.5 million in Series B financing

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

LumiThera has closed $5.5 million in Series B financing to support development of its LT-300 device for treating dry age-related macular degeneration, according to a company press release.

The lead investor was WaterStone Capital, with RPR Venture as a co-investor.

Proceeds from the financing will be used to continue the company’s work obtaining regulatory clearances in Europe and additional countries outside of the United States.

“We are pleased with the investor interest in the company and have oversubscribed the Series B round,” Clark Tedford, PhD, president and CEO of LumiThera, said in the release. “This is an exciting time for the company, and the infusion of new capital will allow us to execute on our multicenter clinical trials and initial [outside the United States] commercialization activities.”

The LT-300 light delivery system is currently the subject of a prospective, randomized, double-masked clinical trial in 30 dry AMD patients, the release said.